Targeted drug delivery using iRGD peptide for solid cancer treatment

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Solid tumors, including pancreatic cancer, often exhibit poor prognosis due to challenges in therapeutic delivery.
• Pathological abnormalities in tumor vasculature impede drug access and reduce bioavailability.
• Nanoparticle-based drug delivery systems offer potential but face similar vascular access limitations.

Purpose of the Study:

• To review the design and implementation strategies for iRGD peptide-mediated tumor targeting.
• To elucidate the mechanism of tumor transcytosis facilitated by iRGD.
• To discuss the personalized application of iRGD technology based on biomarker expression.

Main Methods:

• Summarizing existing research on iRGD peptide conjugation and co-administration with nanocarriers.
• Analyzing the working principle of iRGD peptide in facilitating tumor penetration.
• Reviewing studies on the correlation between neuropilin-1 expression and iRGD efficacy.

Main Results:

• iRGD peptide enables nanocarriers to access solid tumors via a transcytosis mechanism, independent of leaky vasculature.
• This bypass mechanism leads to enhanced nanoparticle distribution and improved therapeutic efficacy.
• The in vivo effect of iRGD is patient-specific, correlating with neuropilin-1 expression levels on tumor vasculature.

Conclusions:

• iRGD peptide-mediated tumor targeting represents a significant advancement in overcoming drug delivery barriers in solid tumors.
• Understanding the transcytosis mechanism is key to optimizing nanoparticle delivery.
• Personalized medicine approaches, considering neuropilin-1 expression, are essential for the successful clinical translation of iRGD technology.